Additionally, in a B16F10 melanoma model, combined treatment with epinephrine and propranolol decreases the in vitro proliferative activity of cancer cells, suggesting a potential modulating role of the β-AR signaling pathway in the antiproliferative action of the catecholamine epinephrine [2]. The gene discussed is ADRB2; the disease is melanoma.